Skip to main content
. 2023 Oct 3;101(14):e1391–e1401. doi: 10.1212/WNL.0000000000207663

Figure 1. Participant Flow Diagram.

Figure 1

*Two participants who were originally assigned to placebo received semorinemab. OLE = open-label extension.